hero section gradient
15 handpicked stocks

Public Infrastructure Builders

These foundational companies build and maintain the essential infrastructure that powers our economies. Their appeal comes from securing long-term government contracts that provide reliable growth and shield them from typical market volatility.

Author avatar

Han Tan | Market Analyst

Published on June 17

Your Basket's Financial Footprint

Summary and investor takeaways for the 'Public Infrastructure Builders' basket based on provided market capitalisation breakdown.

Key Takeaways for Investors:
  • Large-cap dominance tends to reduce volatility, offering more stable, market-like performance and lower idiosyncratic risk.
  • Suitable as a core holding for broad infrastructure exposure, not for short-term speculative trading.
  • Expect steady, long-term appreciation rather than explosive short-term gains; growth likely moderate and gradual.
Total Market Cap
  • VMC: $39.32B

  • STRL: $11.19B

  • PWR: $65.18B

  • Other

About This Group of Stocks

1

Our Expert Thinking

Infrastructure is the backbone of economic development and national security. These companies deliver critical projects like roads, bridges, and power grids through multi-year government contracts, creating predictable revenue streams less vulnerable to economic cycles.

2

What You Need to Know

Infrastructure stocks tend to perform with greater stability over time, fueled by essential public spending that continues regardless of economic conditions. Recent trillion-dollar government initiatives have created a powerful tailwind that should benefit these companies for years to come.

3

Why These Stocks

Each company was selected for its proven track record of winning and executing major government contracts. These industry leaders have the scale, expertise, and capabilities to handle complex public works projects, positioning them to capitalize on the global infrastructure renewal trend.

Why You'll Want to Watch These Stocks

🏗️

Building the Future

Infrastructure spending is at a historic high with trillion-dollar bills pumping money directly into these companies' core businesses. This isn't a short trend - it's a decades-long opportunity.

💰

Recession-Resistant Revenue

While other sectors might struggle during economic downturns, these companies often continue to thrive on government contracts that remain funded regardless of market conditions.

🔄

The Endless Renewal Cycle

Infrastructure isn't built once - it requires constant maintenance and eventual replacement. These companies benefit from both new construction and the never-ending need for updates to aging systems.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Tech Stocks (AI Valuation Reset) Present Potential Entry

Tech Stocks (AI Valuation Reset) Present Potential Entry

Recent market turmoil, driven by concerns over AI stock valuations, has led to a significant drop in global markets. This correction creates a potential opportunity to invest in fundamentally sound technology companies at more attractive prices.

Walmart Succession Plan Explained | Market Effects

Walmart Succession Plan Explained | Market Effects

Walmart announced a CEO transition, with veteran John Furner taking the helm, which could create opportunities for competitors. This leadership change at a retail giant may cause short-term uncertainty, potentially benefiting other major players in the retail space.

Biotech Buyout Candidates (Post-Merck Acquisition)

Biotech Buyout Candidates (Post-Merck Acquisition)

Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.

Frequently Asked Questions